PAVmed (PAVM) Cash & Equivalents (2015 - 2025)

PAVmed's Cash & Equivalents history runs 11 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 29.79% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a 29.79% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 29.79% from the prior year.
• Cash & Equivalents retreated to $1.5 million in Q4 2025 per PAVM's latest filing, from $3.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $77.3 million in Q4 2021 and bottomed at $1.2 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $36.6 million (2023), against an average of $33.9 million.
• Across the five-year window, Cash & Equivalents surged 510.31% in 2021 and sank 93.97% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $77.3 million in 2021, then slumped by 48.56% to $39.7 million in 2022, then sank by 50.59% to $19.6 million in 2023, then sank by 93.97% to $1.2 million in 2024, then grew by 29.79% to $1.5 million in 2025.
• Per Business Quant, the three latest PAVM Cash & Equivalents figures stand at $1.5 million (Q4 2025), $3.1 million (Q3 2025), and $36.0 million (Q2 2025).